VYGR — Voyager Therapeutics, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2016-01-04.
Performance
Technicals
Others in Healthcare
Measured signals that fired on VYGR
| date | signal | measured base rate |
|---|---|---|
| 2026-08-03 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
| 2026-07-15 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
| 2026-05-19 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
| 2026-05-15 | Short volume far above its own normal short | -0.76% over 21 days · t = -2.79 · n = 5,897 statistically distinguishable from its control group |
| 2026-04-10 | Short volume far above its own normal short | -0.76% over 21 days · t = -2.79 · n = 5,897 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-04-02 | Sandrock Alfred President and CEO | Open-market sale 10b5-1 plan | 11.5K | 3.87 | 44.5K |
| 2026-04-01 | Shiferman Gregory L. SVP and General Counsel | Grant or award | 50.0K | 0.00 | 0 |
| 2026-02-24 | Sandrock Alfred President and CEO | Open-market sale 10b5-1 plan | 14.2K | 3.79 | 53.8K |
| 2026-02-24 | Swartz Robin COO & CBO | Open-market sale 10b5-1 plan | 6.5K | 3.77 | 24.3K |
| 2026-02-24 | Jorgensen Nathan D. Chief Financial Officer | Open-market sale 10b5-1 plan | 4.7K | 3.77 | 17.6K |
| 2026-02-24 | Carter Todd Alfred Chief Scientific Officer | Open-market sale 10b5-1 plan | 4.2K | 3.76 | 15.7K |
| 2026-02-18 | Sandrock Alfred President and CEO | Open-market sale 10b5-1 plan | 11.7K | 3.41 | 40.0K |
| 2026-02-18 | Swartz Robin COO & CBO | Open-market sale 10b5-1 plan | 3.9K | 3.44 | 13.4K |
| 2026-02-18 | Carter Todd Alfred Chief Scientific Officer | Open-market sale 10b5-1 plan | 3.3K | 3.44 | 11.4K |
| 2026-02-10 | Sandrock Alfred President and CEO | Open-market sale | 12.2K | 3.78 | 46.1K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| BlackRock, Inc. | 21.5M | 5.6M |
| ARMISTICE CAPITAL, LLC | 13.5M | 3.5M |
| MILLENNIUM MANAGEMENT LLC | 13.2M | 3.4M |
| Vestal Point Capital, LP | 11.6M | 3.0M |
| VANGUARD CAPITAL MANAGEMENT LLC | 8.8M | 2.3M |
| Opaleye Management Inc. | 4.4M | 1.1M |
| Erste Asset Management GmbH | 4.2M | 1.1M |
| GEODE CAPITAL MANAGEMENT, LLC | 4.1M | 1.0M |
| STATE STREET CORP | 3.7M | 948.2K |
| DIMENSIONAL FUND ADVISORS LP | 3.4M | 875.6K |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| SCHEDULE 13G/A | 2026-08-14 | — | on EDGAR ↗ |
| 8-K | 2026-08-06 | 2026-08-06 | on EDGAR ↗ |
| 10-Q | 2026-08-06 | 2026-06-30 | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-07-31 | — | on EDGAR ↗ |
| 8-K | 2026-07-13 | 2026-07-13 | on EDGAR ↗ |
| 4 | 2026-06-11 | 2026-06-09 | on EDGAR ↗ |
| 4 | 2026-06-11 | 2026-06-09 | on EDGAR ↗ |
| 4 | 2026-06-11 | 2026-06-09 | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Voyager Therapeutics, Inc. (VYGR) filed form SCHEDULE 13G/A · 2026-08-14 · SEC EDGAR
Ask the AI about VYGR
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →